Quantcast

Latest Lilly Stories

2014-06-14 12:20:45

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.(1) The head-to-head study compared...

2014-06-14 12:20:40

Companies present comprehensive data for LY2963016, investigational new insulin glargine product SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- For the first time today, Eli Lilly and Company (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals Inc. presented data showing that LY2963016, the alliance's investigational new insulin glargine product, has a similar safety and efficacy profile to currently marketed insulin glargine (Lantus(®)).(1,2,3,4,5,6) Results from these Phase I and Phase III...

2014-06-11 08:29:11

INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant. Encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall...

2014-06-09 08:30:07

Company to highlight late-stage pipeline molecules, including once-weekly dulaglutide and basal insulin peglispro INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced 76 abstracts to be presented June 13-17 at the 74(th) American Diabetes Association Scientific Sessions(®) in San Francisco, highlighting the company's long-standing commitment to advancing scientific knowledge in the field of diabetes management. Forty-three of these abstracts will be...

2014-06-09 08:29:57

· Data for investigational compounds LY2963016, empagliflozin and empagliflozin/linagliptin combination tablet highlight robust alliance pipeline RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- More than 40 posters, abstracts and oral presentations will demonstrate the breadth and depth of the Boehringer Ingelheim (BI) and Eli Lilly and Company (NYSE: LLY) diabetes portfolio at the 74(th) American Diabetes Association (ADA) Scientific Sessions® in San Francisco, June 13-17....

2014-06-05 16:22:51

-- System is one of the largest for a pharmaceutical company worldwide, the largest for a pharmaceutical company in New Jersey -- BEDMINSTER, N.J., June 5, 2014 /PRNewswire/ -- KDC Solar LLC has commenced commercial operations of its 9.95-megawatt (MW) solar panel system in New Jersey. The system will provide electricity to Eli Lilly and Company's ImClone biopharmaceutical operations in Branchburg, N.J. Lilly acquired ImClone Systems in 2008....

2014-06-02 20:22:44

-- REVEL Data Published in The Lancet, Presented at Annual ASCO Meeting -- CHICAGO, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA((TM)) (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract...

2014-06-02 08:26:14

INDIANAPOLIS, June 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. This website, which houses data from several clinical trial sponsors, was created in support of ongoing efforts by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) to increase access to and...

2014-05-30 04:22:13

HILDEN, Germany, and GERMANTOWN, Maryland, May 30, 2014 /PRNewswire/ -- - Fourth oncology project with Lilly expands QIAGEN's Personalized Healthcare pipeline - Development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with innovative cancer therapies under development by Lilly - Project to include assays for QIAGEN's new multi-modal, multi-analyte Modaplex...

2014-05-28 08:30:29

Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Eli Lilly and Company (NYSE: LLY) today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED). Under the terms of the...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related